Fractional Flow Reserve to Guide Treatment of Patients With Multivessel Coronary Artery Disease
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved..
BACKGROUND: There is limited evidence that fractional flow reserve (FFR) is effective in guiding therapeutic strategy in multivessel coronary artery disease (CAD) beyond prespecified percutaneous coronary intervention or coronary graft surgery candidates.
OBJECTIVES: The FUTURE (FUnctional Testing Underlying coronary REvascularization) trial aimed to evaluate whether a treatment strategy based on FFR was superior to a traditional strategy without FFR in the treatment of multivessel CAD.
METHODS: The FUTURE trial is a prospective, randomized, open-label superiority trial. Multivessel CAD candidates were randomly assigned (1:1) to treatment strategy based on FFR in all stenotic (≥50%) coronary arteries or to a traditional strategy without FFR. In the FFR group, revascularization (percutaneous coronary intervention or surgery) was indicated for FFR ≤0.80 lesions. The primary endpoint was a composite of major adverse cardiac or cerebrovascular events at 1 year.
RESULTS: The trial was stopped prematurely by the data safety and monitoring board after a safety analysis and 927 patients were enrolled. At 1-year follow-up, by intention to treat, there were no significant differences in major adverse cardiac or cerebrovascular events rates between groups (14.6% in the FFR group vs 14.4% in the control group; hazard ratio: 0.97; 95% confidence interval: 0.69-1.36; P = 0.85). The difference in all-cause mortality was nonsignificant, 3.7% in the FFR group versus 1.5% in the control group (hazard ratio: 2.34; 95% confidence interval: 0.97-5.18; P = 0.06), and this was confirmed with a 24 months' extended follow-up. FFR significantly reduced the proportion of revascularized patients, with more patients referred to exclusively medical treatment (P = 0.02).
CONCLUSIONS: In patients with multivessel CAD, we did not find evidence that an FFR-guided treatment strategy reduced the risk of ischemic cardiovascular events or death at 1-year follow-up. (Functional Testing Underlying Coronary Revascularisation; NCT01881555).
| Errataetall: |
CommentIn: J Am Coll Cardiol. 2021 Nov 9;78(19):1886-1889. - PMID 34736564 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Journal of the American College of Cardiology - 78(2021), 19 vom: 09. Nov., Seite 1875-1885 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rioufol, Gilles [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Coronary artery disease |
|---|
| Anmerkungen: |
Date Completed 03.01.2022 Date Revised 14.06.2022 published: Print ClinicalTrials.gov: NCT01881555 CommentIn: J Am Coll Cardiol. 2021 Nov 9;78(19):1886-1889. - PMID 34736564 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jacc.2021.08.061 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332746623 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332746623 | ||
| 003 | DE-627 | ||
| 005 | 20231225220218.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacc.2021.08.061 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1109.xml |
| 035 | |a (DE-627)NLM332746623 | ||
| 035 | |a (NLM)34736563 | ||
| 035 | |a (PII)S0735-1097(21)06221-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rioufol, Gilles |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fractional Flow Reserve to Guide Treatment of Patients With Multivessel Coronary Artery Disease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2022 | ||
| 500 | |a Date Revised 14.06.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT01881555 | ||
| 500 | |a CommentIn: J Am Coll Cardiol. 2021 Nov 9;78(19):1886-1889. - PMID 34736564 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: There is limited evidence that fractional flow reserve (FFR) is effective in guiding therapeutic strategy in multivessel coronary artery disease (CAD) beyond prespecified percutaneous coronary intervention or coronary graft surgery candidates | ||
| 520 | |a OBJECTIVES: The FUTURE (FUnctional Testing Underlying coronary REvascularization) trial aimed to evaluate whether a treatment strategy based on FFR was superior to a traditional strategy without FFR in the treatment of multivessel CAD | ||
| 520 | |a METHODS: The FUTURE trial is a prospective, randomized, open-label superiority trial. Multivessel CAD candidates were randomly assigned (1:1) to treatment strategy based on FFR in all stenotic (≥50%) coronary arteries or to a traditional strategy without FFR. In the FFR group, revascularization (percutaneous coronary intervention or surgery) was indicated for FFR ≤0.80 lesions. The primary endpoint was a composite of major adverse cardiac or cerebrovascular events at 1 year | ||
| 520 | |a RESULTS: The trial was stopped prematurely by the data safety and monitoring board after a safety analysis and 927 patients were enrolled. At 1-year follow-up, by intention to treat, there were no significant differences in major adverse cardiac or cerebrovascular events rates between groups (14.6% in the FFR group vs 14.4% in the control group; hazard ratio: 0.97; 95% confidence interval: 0.69-1.36; P = 0.85). The difference in all-cause mortality was nonsignificant, 3.7% in the FFR group versus 1.5% in the control group (hazard ratio: 2.34; 95% confidence interval: 0.97-5.18; P = 0.06), and this was confirmed with a 24 months' extended follow-up. FFR significantly reduced the proportion of revascularized patients, with more patients referred to exclusively medical treatment (P = 0.02) | ||
| 520 | |a CONCLUSIONS: In patients with multivessel CAD, we did not find evidence that an FFR-guided treatment strategy reduced the risk of ischemic cardiovascular events or death at 1-year follow-up. (Functional Testing Underlying Coronary Revascularisation; NCT01881555) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a coronary artery disease | |
| 650 | 4 | |a coronary revascularization strategy | |
| 650 | 4 | |a fractional flow reserve | |
| 700 | 1 | |a Dérimay, François |e verfasserin |4 aut | |
| 700 | 1 | |a Roubille, François |e verfasserin |4 aut | |
| 700 | 1 | |a Perret, Thibault |e verfasserin |4 aut | |
| 700 | 1 | |a Motreff, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Angoulvant, Denis |e verfasserin |4 aut | |
| 700 | 1 | |a Cottin, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Meunier, Ludovic |e verfasserin |4 aut | |
| 700 | 1 | |a Cetran, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Cayla, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Harbaoui, Brahim |e verfasserin |4 aut | |
| 700 | 1 | |a Wiedemann, Jean-Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Van Belle, Éric |e verfasserin |4 aut | |
| 700 | 1 | |a Pouillot, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Noirclerc, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Morelle, Jean-François |e verfasserin |4 aut | |
| 700 | 1 | |a Soto, François-Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Caussin, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Bertrand, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Lefèvre, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Dupouy, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Lesault, Pierre-François |e verfasserin |4 aut | |
| 700 | 1 | |a Albert, Franck |e verfasserin |4 aut | |
| 700 | 1 | |a Barthelemy, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Koning, René |e verfasserin |4 aut | |
| 700 | 1 | |a Leborgne, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Barnay, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Chapon, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Armero, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Lafont, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Piot, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Amaz, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Vaz, Bernadette |e verfasserin |4 aut | |
| 700 | 1 | |a Benyahya, Lakhdar |e verfasserin |4 aut | |
| 700 | 1 | |a Varillon, Yvonne |e verfasserin |4 aut | |
| 700 | 1 | |a Ovize, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Mewton, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Finet, Gérard |e verfasserin |4 aut | |
| 700 | 0 | |a FUTURE Trial Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Leborgne, Laurent |e investigator |4 oth | |
| 700 | 1 | |a Fournier, Alexandre |e investigator |4 oth | |
| 700 | 1 | |a Jarry, Geneviève |e investigator |4 oth | |
| 700 | 1 | |a Leleu, François |e investigator |4 oth | |
| 700 | 1 | |a Malaquin, Dorothée |e investigator |4 oth | |
| 700 | 1 | |a Mirode, Anfani |e investigator |4 oth | |
| 700 | 1 | |a Belle, Loïc |e investigator |4 oth | |
| 700 | 1 | |a Mangin, Lionel |e investigator |4 oth | |
| 700 | 1 | |a Noirclerc, Nathalie |e investigator |4 oth | |
| 700 | 1 | |a Barnay, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Hirsch, Jean-Lou |e investigator |4 oth | |
| 700 | 1 | |a Metge, Marc |e investigator |4 oth | |
| 700 | 1 | |a Pansiery, Michel |e investigator |4 oth | |
| 700 | 1 | |a Soto, FrançoisXavier |e investigator |4 oth | |
| 700 | 1 | |a Boge, Antoine |e investigator |4 oth | |
| 700 | 1 | |a HadjHamou, Kamel |e investigator |4 oth | |
| 700 | 1 | |a Miliani, Ichem |e investigator |4 oth | |
| 700 | 1 | |a Molins, Guillaume |e investigator |4 oth | |
| 700 | 1 | |a Mourot, Stéphane |e investigator |4 oth | |
| 700 | 1 | |a Pelletier, Marion |e investigator |4 oth | |
| 700 | 1 | |a Ressencourt, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Schaad, Frédéric |e investigator |4 oth | |
| 700 | 1 | |a Coste, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Chasseriaud, Warren |e investigator |4 oth | |
| 700 | 1 | |a Cetran, Laura |e investigator |4 oth | |
| 700 | 1 | |a Poustis, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Cetran, Laura |e investigator |4 oth | |
| 700 | 1 | |a Morelle, Jean-Francois |e investigator |4 oth | |
| 700 | 1 | |a Albert, Franck |e investigator |4 oth | |
| 700 | 1 | |a Demicheli, Thibaud |e investigator |4 oth | |
| 700 | 1 | |a Range, Grégroire |e investigator |4 oth | |
| 700 | 1 | |a Thuaire, Christophe |e investigator |4 oth | |
| 700 | 1 | |a Motreff, Pascal |e investigator |4 oth | |
| 700 | 1 | |a Barber-Chamoux, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Combaret, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Malclès, Guilhem |e investigator |4 oth | |
| 700 | 1 | |a Souteyrand, Géraud |e investigator |4 oth | |
| 700 | 1 | |a Cottin, Yves |e investigator |4 oth | |
| 700 | 1 | |a Buffet, Philippe |e investigator |4 oth | |
| 700 | 1 | |a Gudjonvick, Aurélie |e investigator |4 oth | |
| 700 | 1 | |a L'Huillier, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Lorgis, Luc |e investigator |4 oth | |
| 700 | 1 | |a Richard, Carole |e investigator |4 oth | |
| 700 | 1 | |a Bertrand, Bernard |e investigator |4 oth | |
| 700 | 1 | |a Baronne-Rochette, Gilles |e investigator |4 oth | |
| 700 | 1 | |a Bouvaist, Hélène |e investigator |4 oth | |
| 700 | 1 | |a Marlière, Stéphanie |e investigator |4 oth | |
| 700 | 1 | |a Ormezzano, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Vanzetto, Gérald |e investigator |4 oth | |
| 700 | 1 | |a Meunier, Ludovic |e investigator |4 oth | |
| 700 | 1 | |a Trouillet, Charlotte |e investigator |4 oth | |
| 700 | 1 | |a Valy, Yann |e investigator |4 oth | |
| 700 | 1 | |a Lesault, Pierre-François |e investigator |4 oth | |
| 700 | 1 | |a VanBelle, Eric |e investigator |4 oth | |
| 700 | 1 | |a Bauters, Christophe |e investigator |4 oth | |
| 700 | 1 | |a Delhaye, Cédric |e investigator |4 oth | |
| 700 | 1 | |a Lemesle, Gilles |e investigator |4 oth | |
| 700 | 1 | |a Rihani, Riadh |e investigator |4 oth | |
| 700 | 1 | |a Graux, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Lemahieu, Jean-Michel |e investigator |4 oth | |
| 700 | 1 | |a Harbaoui, Brahim |e investigator |4 oth | |
| 700 | 1 | |a Besnard, Cyril |e investigator |4 oth | |
| 700 | 1 | |a Courand, Pierre-Yves |e investigator |4 oth | |
| 700 | 1 | |a Dauphin, Raphaël |e investigator |4 oth | |
| 700 | 1 | |a Lantelme, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Perret, Thibault |e investigator |4 oth | |
| 700 | 1 | |a Caignault, Jean-Raymond |e investigator |4 oth | |
| 700 | 1 | |a Dubreuil, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Ranc, Sylvain |e investigator |4 oth | |
| 700 | 1 | |a Ritz, Bernard |e investigator |4 oth | |
| 700 | 1 | |a Rioufol, Gilles |e investigator |4 oth | |
| 700 | 1 | |a Bergerot, Cyrille |e investigator |4 oth | |
| 700 | 1 | |a Bochaton, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Bonnefoy-Cudraz, Eric |e investigator |4 oth | |
| 700 | 1 | |a Bresson, Didier |e investigator |4 oth | |
| 700 | 1 | |a Dementhon, Julie |e investigator |4 oth | |
| 700 | 1 | |a Derimay, François |e investigator |4 oth | |
| 700 | 1 | |a Finet, Gérard |e investigator |4 oth | |
| 700 | 1 | |a Green, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Prieur, Cyril |e investigator |4 oth | |
| 700 | 1 | |a Sanchez, Ingrid |e investigator |4 oth | |
| 700 | 1 | |a Zouaghi, Oualid |e investigator |4 oth | |
| 700 | 1 | |a Arméro, Sébastien |e investigator |4 oth | |
| 700 | 1 | |a Lefèvre, Thierry |e investigator |4 oth | |
| 700 | 1 | |a Ben-Amer, Hakim |e investigator |4 oth | |
| 700 | 1 | |a Chevalier, Bernard |e investigator |4 oth | |
| 700 | 1 | |a Garot, Philippe |e investigator |4 oth | |
| 700 | 1 | |a Hovasse, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Louvard, Yves |e investigator |4 oth | |
| 700 | 1 | |a Morice, Marie-Claude |e investigator |4 oth | |
| 700 | 1 | |a Tavolaro, Oscar |e investigator |4 oth | |
| 700 | 1 | |a Unterseeh, Thierry |e investigator |4 oth | |
| 700 | 1 | |a Dupouy, Patrick |e investigator |4 oth | |
| 700 | 1 | |a Roubille, François |e investigator |4 oth | |
| 700 | 1 | |a Cung, DinhThienTri |e investigator |4 oth | |
| 700 | 1 | |a Macia, Jean-Christophe |e investigator |4 oth | |
| 700 | 1 | |a Piot, Christophe |e investigator |4 oth | |
| 700 | 1 | |a Levy, Gilles |e investigator |4 oth | |
| 700 | 1 | |a Roth, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Bresson, Didier |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American College of Cardiology |d 1987 |g 78(2021), 19 vom: 09. Nov., Seite 1875-1885 |w (DE-627)NLM012608602 |x 1558-3597 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2021 |g number:19 |g day:09 |g month:11 |g pages:1875-1885 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacc.2021.08.061 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2021 |e 19 |b 09 |c 11 |h 1875-1885 | ||